Abnormal regulation of adenosine 3',5'-monophosphate and corticosterone formation in an adrenocortical carcinoma

• Published in: The Journal of clinical investigation 1969-09, Vol.48 (9), p.1733-1739
• Main Authors: Ney, R L, Hochella, N J, Grahame-Smith, D G, Dexter, R N, Butcher, R W
• Format: Article
• Language: English
• Subjects: Adenine Nucleotides - metabolism; Adenosine Triphosphate - analysis; Adenylyl Cyclases - analysis; Adrenal Gland Neoplasms - metabolism; Adrenal Glands - drug effects; Adrenocorticotropic Hormone - pharmacology; Animals; Corticosterone - biosynthesis; Culture Techniques; Cyclic AMP - metabolism; NADP - pharmacology; Neoplasm Transplantation; Neoplasms, Experimental - metabolism; Phosphoric Monoester Hydrolases - analysis; Rats
• ISSN: 0021-9738
• DOI: 10.1172/JCI106139

A spontaneously occurring rat adrenocortical carcinoma which produces corticosterone was maintained by transplantation. The carcinoma appeared to utilize corticosterone biosynthetic steps similar to those of the normal adrenal, but the tumor produced only about 1-10% as much corticosterone per unit tissue weight as nontumorous adrenal glands. The tumor demonstrated little or no increase in corticosterone production in response to adrenocorticotropic hormone (ACTH) either in vivo or in vitro. In normal adrenals, ACTH increases the activity of adenyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to adenosine-3',5'-monophosphate (cyclic AMP), the latter then serving as an intracellular regulator of steroidogenesis. ACTH failed to increase cyclic AMP levels in the tumor in vivo or in slices in vitro, conditions under which there were 50- and 20-fold increases in nontumorous adrenals. However, in homogenates fortified with exogenous ATP, adenyl cyclase activity was comparable in the tumor and adrenals, and cyclic AMP formation was increased 3-fold by ACTH in each. As measured in homogenates, the tumor did not possess a greater ability to destroy cyclic AMP than did normal adrenals. Although ATP levels in the carcinoma were found to be considerably lower than those in normal adrenals, it was not clear that this finding can explain the inability of ACTH to increase cyclic AMP levels in intact tumor cells. While the failure to normally influence cyclic AMP levels in the carcinoma cells could be an important factor in the lack of a steroid response to ACTH, several lines of evidence suggest that the tumor possesses one or more additional abnormalities in the regulation of steroidogenesis. First, in the absence of ACTH stimulation, the tissue concentrations of cyclic AMP were comparable in the tumor and in nontumorous adrenals, but these cyclic AMP levels were associated with a lower level of steroidogenesis in the tumor. Second, tumor slices failed to increase corticosterone production when incubated with cyclic AMP, in contrast to 5-fold increases observed with nontumorous adrenals.